Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
vandetanib (Caprelsa®)
Reference No. 3349
Publication date:
08/08/2017
Appraisal information
vandetanib (Caprelsa®) 100 mg film-coated tablet
vandetanib (Caprelsa®) 300 mg film-coated tablet
Company:
Genzyme Therapeutics
BNF category:
Malignant disease and immunosupression
NMG meeting date:
Not scheduled
AWMSG meeting date:
Not scheduled
Submission Type:
Nonsubmission
Status:
Not endorsed
Advice No:
Not available
Ratification by Welsh Government:
07/08/2017
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
In the absence of a submission from the holder of the marketing authorisation, vandetanib (Caprelsa®) cannot be endorsed for use within NHS Wales for the treatment of aggressive and symptomatic medullary thyroid cancer in children and adolescents aged 5 years to 18 years with unresectable locally advanced or metastatic disease.
Statement of Advice (SOA)
Download
Vandetanib (Caprelsa) 3349 SOA
